Biomarkers in Alzheimer's disease: a review.
Biomarkers in Alzheimer's disease: a review.
复制标题
DOI：
10.5402/2012/984786
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Bhaskar M
中科院分区：
文献类型：
--
作者：
Chintamaneni M;Bhaskar M
阿尔茨海默病是最常见的痴呆症，影响着全世界数百万人。目前只能通过临床评估和死后脑部病理来诊断。开发有效的阿尔茨海默病生物标志物对于提高诊断和加速新疗法的开发至关重要。生化和神经影像学标志物可以促进诊断，预测AD前期轻度认知障碍（MCI）的进展，并用于监测疾病改善治疗的疗效。脑脊液Aβ40、Aβ42、总tau蛋白和磷酸化tau蛋白水平对AD有诊断价值。上述脑脊液标志物的联合测量对于预测MCI向AD进展的风险是有用的。新的潜在生物标志物正在出现，脑脊液或血浆标志物谱可能最终成为临床医生准确诊断和管理阿尔茨海默病工具包的一部分。这些生物标志物与临床评估、神经心理测试和神经影像学一起，可以在未来对阿尔茨海默病和相关疾病实现更高的诊断准确性。
Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide. It is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. The development of validated biomarkers for Alzheimer's disease is essential to improve diagnosis and accelerate the development of new therapies. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. Cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau, and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers along with clinical assessment, neuropsychological testing, and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future.